drugset / Trial / NCT04032847
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2019-07-08
- Primary completion
- 2024-09-26
- Completion
- 2024-09-26
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATL001 | Cell therapy | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |